The positively-breathless predictions of the death of any US health care reform bill -- based on this one Massachusetts-specific event -- are simply overheated. Just as his Cosmo erh, spread was.
Matt Herper, a few minutes ago, writing for Forbes, offers some sensible thoughts (quoting others) -- do go read it all:
. . . .ObamaCare's fate isn't quite sealed yet. But Richard Evans, 47, a former Roche executive and Sanford C. Bernstein analyst who now runs Sector & Sovereign, a New York health care analysis boutique that tries to wring financial bets out of politicalheadwinds, is bullish on health insurance stocks, like UnitedHealth, Aetna and WellCare. But he's steering clear of drug makers like Pfizer and Merck. (He recommends sub-sectors, not individual companies). . . .
The insurers are going to be boosted, he predicts, because of a longer flu season and because consumers are rushing to spend on health care in the fear that they might lose their jobs. Meanwhile, investors are underestimating the havoc that patent expirations are going to wreak on drug company margins. . . .
Do go read it all, to find out why. Boy -- these Republicans are a classy lot.
